Trial · NCT02936752
Adverse events422
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 422
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | hypovolemia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | hypovolemia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | mitral regurgitation | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | mitral regurgitation | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | Mitral valve disease | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Mitral valve disease | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Mitral valve regurgitation | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | Mitral valve regurgitation | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | Paroxysmal atrial tachycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Paroxysmal atrial tachycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 2 | 22 | 2 |
| other | Sinus bradycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Ventricular arrhythmia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Ventricular arrhythmia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Ventricular tachycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Ventricular tachycardia | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | volume overload | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | volume overload | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02936752/events?page=2